Detalles de la búsqueda
1.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636444
2.
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
EBioMedicine
; 92: 104633, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37244159
3.
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer
; 11(4)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085190
4.
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Cancer Discov
; 12(10): 2280-2307, 2022 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35929803
5.
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.
Oncoimmunology
; 9(1): 1774298, 2020 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32934879
6.
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer.
J Immunother Cancer
; 8(1)2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32448799
Resultados
1 -
6
de 6
1
Próxima >
>>